EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments. The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology. The company released its full-year 2024 results and updated investors on the tremendous progress made. With the timeline laid out by the company, we believe 2025 will be an exciting year for EVAX.
